Transcription of 2020 Annual Report
{{id}} {{{paragraph}}}
Example: bankruptcy
2020 Annual Report
2020 Annual ReportOur MissionTo discover, develop and deliver innovative medicines that help patients prevail over serious diseasesOur VisionTo be the world's leading biopharma company that transforms patients' lives through scienceOur ValuesIntegrity | Innovation | Urgency | Passion | Accountability | InclusionCover image: During a year when most of us were separated by the pandemic, our global collective efforts ensured that individual contributions came together to make a significant impact for Full-Year RevenuesGAAP Full-Year Change vs. Prior Year*63%Worldwide Revenues$ Forma Full-Year Change vs. Prior Year**7% We created a leading biopharma company that combines the agility of a biotech company with the reach and resources of an established pharmaceutical corporation. We worked hard to deliver on our mission by maintaining an uninterrupted supply of medicines to patients, launching new products and continuing to conduct clinical trials where possible, while navigating the challenges of a worldwide pandemic.
Opdivo (nivolumab) plus Yervoy (ipilimumab). Opdivo-based treatments are helping improve outcomes as first-line treatment for lung cancer patients and showing promise in the adjuvant treatment setting, providing new and earlier treatment options to cancer patients. We continued to advance our late-stage pipeline with positive top-line results
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: